On September 21, SKB BIO rose 3.34% in regular trading, trading at 475.8 HKD/share, with turnover of approximately HKD 13.45 million. The gain comes amid continued positive sentiment following a series of recent catalysts.
SKB BIO reported its first-ever half-year profit since listing, posting attributable net income of RMB 388 million for H1, compared with a loss of RMB 145.2 million a year earlier. Revenue reached RMB 978 million, up 2.9% year-over-year, while drug sales surged 112% to RMB 657 million driven by multiple newly launched innovative drugs. Gross margin improved to 75.3% from 69.4%, and operating cash flow turned positive to RMB 339 million.
On the pipeline front, partner Windward Bio reported positive Phase 2 interim results for SKB378/WIN378 in asthma treatment and initiated Phase 3 trials evaluating a twice-yearly dosing regimen. The drug demonstrated favorable tolerability with no treatment-related serious adverse events. Multiple brokerages including UBS, Bank of America, and CLSA raised target prices, with UBS setting the highest at HKD 678, all maintaining buy ratings.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments